227 related articles for article (PubMed ID: 20233213)
1. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.
Miller TW; Isenberg JS; Roberts DD
Br J Pharmacol; 2010 Apr; 159(7):1542-7. PubMed ID: 20233213
[TBL] [Abstract][Full Text] [Related]
2. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
3. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
5. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.
Ramanathan S; Mazzalupo S; Boitano S; Montfort WR
Biochemistry; 2011 Sep; 50(36):7787-99. PubMed ID: 21823650
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.
Yao M; Roberts DD; Isenberg JS
Pharmacol Res; 2011 Jan; 63(1):13-22. PubMed ID: 20971192
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.
Schmidt K; Schrammel A; Koesling D; Mayer B
Mol Pharmacol; 2001 Feb; 59(2):220-4. PubMed ID: 11160856
[TBL] [Abstract][Full Text] [Related]
9. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Turgut NH; Temiz TK; Turgut B; Karadas B; Parlak M; Bagcivan I
Can J Physiol Pharmacol; 2013 Oct; 91(10):797-803. PubMed ID: 24144050
[TBL] [Abstract][Full Text] [Related]
11. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
Roger S; Paysant J; Badier-Commander C; Cordi A; Verbeuren TJ; Félétou M
Vascul Pharmacol; 2010; 53(5-6):281-7. PubMed ID: 20933607
[TBL] [Abstract][Full Text] [Related]
12. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
13. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
Dismuke WM; Sharif NA; Ellis DZ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
15. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
16. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
Hobbs AJ; Moncada S
Vascul Pharmacol; 2003 Oct; 40(3):149-54. PubMed ID: 13678646
[TBL] [Abstract][Full Text] [Related]
18. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
[TBL] [Abstract][Full Text] [Related]
19. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
20. The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Kobsar A; Koessler J; Kehrer L; Gambaryan S; Walter U
Thromb Haemost; 2012 Mar; 107(3):521-9. PubMed ID: 22234363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
